FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1984608713> ?p ?o ?g. }

• W1984608713 endingPage "2147" @default.
• W1984608713 startingPage "2140" @default.
• W1984608713 abstract "Suramin is an antitrypanosomal agent with antineoplastic activity, but with serious systemic side effects. We administered Suramin intravesically to determine a concentration with low toxicity but with evidence of a pharmacodynamic effect, to recommend a dose level for phase II trials. This was an open-labelled, non-randomized dose-escalation phase I study. In all, 12 patients with a history of recurrent superficial bladder cancer were grouped into four dose levels (10-150 mg ml(-1) in 60 ml saline). Six catheter instillations at weekly intervals were used. Cystoscopy and biopsy were performed before and 3 months after the start of treatment. Suramin was assayed using high-performance liquid chromatography, vascular endothelial growth factor (VEGF) using ELISA (enzyme-linked immunosorbent assay), and urinary protein profile using surface-enhanced laser desorption ionisation mass spectroscopy (SELDI). Minimal systemic absorption of Suramin was found at the highest dose of 150 mg ml(-1). Urinary VEGF was affected by Suramin at doses above 50 mg ml(-1), corresponding to the estimated threshold of saturation of Suramin binding to urine albumin. SELDI showed a specific disappearance of urinary protein peaks during treatment. Intravesical Suramin shows lack of toxicity and low systemic absorption. The results of this phase I trial support expanded clinical trials of efficacy at a dose of 100 mg ml(-1) intravesically." @default.
• W1984608713 created "2016-06-24" @default.
• W1984608713 creator A5003966873 @default.
• W1984608713 creator A5021892034 @default.
• W1984608713 creator A5029625630 @default.
• W1984608713 creator A5037811990 @default.
• W1984608713 creator A5045004134 @default.
• W1984608713 creator A5075838426 @default.
• W1984608713 creator A5076316924 @default.
• W1984608713 creator A5077441982 @default.
• W1984608713 creator A5078511384 @default.
• W1984608713 creator A5079633934 @default.
• W1984608713 creator A5086097314 @default.
• W1984608713 date "2005-05-31" @default.
• W1984608713 modified "2023-10-09" @default.
• W1984608713 title "Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma" @default.
• W1984608713 cites W1044931647 @default.
• W1984608713 cites W1531755510 @default.
• W1984608713 cites W1603098046 @default.
• W1984608713 cites W1677040759 @default.
• W1984608713 cites W1766226639 @default.
• W1984608713 cites W1967642037 @default.
• W1984608713 cites W1967657886 @default.
• W1984608713 cites W1972580962 @default.
• W1984608713 cites W1976899949 @default.
• W1984608713 cites W1988814101 @default.
• W1984608713 cites W2001764025 @default.
• W1984608713 cites W2008781125 @default.
• W1984608713 cites W2023154792 @default.
• W1984608713 cites W2042049016 @default.
• W1984608713 cites W2045473735 @default.
• W1984608713 cites W2047134070 @default.
• W1984608713 cites W2057147067 @default.
• W1984608713 cites W2068818299 @default.
• W1984608713 cites W2081439037 @default.
• W1984608713 cites W2093754513 @default.
• W1984608713 cites W2095159968 @default.
• W1984608713 cites W2097783657 @default.
• W1984608713 cites W2113944500 @default.
• W1984608713 cites W2123614023 @default.
• W1984608713 cites W2152433281 @default.
• W1984608713 cites W2401029002 @default.
• W1984608713 cites W2420847416 @default.
• W1984608713 cites W2031827488 @default.
• W1984608713 doi "https://doi.org/10.1038/sj.bjc.6602650" @default.
• W1984608713 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2361814" @default.
• W1984608713 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15928663" @default.
• W1984608713 hasPublicationYear "2005" @default.
• W1984608713 type Work @default.
• W1984608713 sameAs 1984608713 @default.
• W1984608713 citedByCount "29" @default.
• W1984608713 countsByYear W19846087132012 @default.
• W1984608713 countsByYear W19846087132013 @default.
• W1984608713 countsByYear W19846087132014 @default.
• W1984608713 countsByYear W19846087132015 @default.
• W1984608713 countsByYear W19846087132016 @default.
• W1984608713 countsByYear W19846087132020 @default.
• W1984608713 countsByYear W19846087132021 @default.
• W1984608713 crossrefType "journal-article" @default.
• W1984608713 hasAuthorship W1984608713A5003966873 @default.
• W1984608713 hasAuthorship W1984608713A5021892034 @default.
• W1984608713 hasAuthorship W1984608713A5029625630 @default.
• W1984608713 hasAuthorship W1984608713A5037811990 @default.
• W1984608713 hasAuthorship W1984608713A5045004134 @default.
• W1984608713 hasAuthorship W1984608713A5075838426 @default.
• W1984608713 hasAuthorship W1984608713A5076316924 @default.
• W1984608713 hasAuthorship W1984608713A5077441982 @default.
• W1984608713 hasAuthorship W1984608713A5078511384 @default.
• W1984608713 hasAuthorship W1984608713A5079633934 @default.
• W1984608713 hasAuthorship W1984608713A5086097314 @default.
• W1984608713 hasBestOaLocation W19846087131 @default.
• W1984608713 hasConcept C126322002 @default.
• W1984608713 hasConcept C126894567 @default.
• W1984608713 hasConcept C170493617 @default.
• W1984608713 hasConcept C2776182878 @default.
• W1984608713 hasConcept C2778769751 @default.
• W1984608713 hasConcept C2779762690 @default.
• W1984608713 hasConcept C2780026642 @default.
• W1984608713 hasConcept C29730261 @default.
• W1984608713 hasConcept C71924100 @default.
• W1984608713 hasConcept C77411442 @default.
• W1984608713 hasConcept C98274493 @default.
• W1984608713 hasConceptScore W1984608713C126322002 @default.
• W1984608713 hasConceptScore W1984608713C126894567 @default.
• W1984608713 hasConceptScore W1984608713C170493617 @default.
• W1984608713 hasConceptScore W1984608713C2776182878 @default.
• W1984608713 hasConceptScore W1984608713C2778769751 @default.
• W1984608713 hasConceptScore W1984608713C2779762690 @default.
• W1984608713 hasConceptScore W1984608713C2780026642 @default.
• W1984608713 hasConceptScore W1984608713C29730261 @default.
• W1984608713 hasConceptScore W1984608713C71924100 @default.
• W1984608713 hasConceptScore W1984608713C77411442 @default.
• W1984608713 hasConceptScore W1984608713C98274493 @default.
• W1984608713 hasIssue "12" @default.
• W1984608713 hasLocation W19846087131 @default.
• W1984608713 hasLocation W19846087132 @default.
• W1984608713 hasLocation W19846087133 @default.
• W1984608713 hasLocation W19846087134 @default.

• next